Direct Meds vs Embody
Direct Meds identifies its oral option as sublingual drops. Embody's current terms describe gum, and its older oral price is no longer a reliable basis for a $20 comparison.
Disclosure: GLP Loss is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Direct Meds
Partner
$249/mo
$297 a month for injectable semaglutide and $399 for tirzepatide, each stated as billed monthly and covering the visit, supplies and shipping with no membership fee. The per-day figures beside them are the same monthly rate divided by the days in a month.
- Prices published with the billing interval stated beside them
- The figure covers medication, visit, supplies and shipping
- A starting dose schedule is published in milligrams
- The state list is published, all states except Mississippi and Louisiana
- Priced well above the typical figure in this category
- Per-day framing makes a large monthly number look small
- The landing page leads with a $147 first month, not the $297 standing rate
- The dispensing pharmacies are unnamed and described inconsistently
Pick it for: Buyers comparing a specifically identified sublingual-drop option
Not for: Anyone shopping this market on price.
Embody
Partner
Current injection offers advertise $69 for semaglutide and $119 for tirzepatide, but the legal terms list different introductory and flat-price programs. Confirm the program, renewal amount and cancellation deadline before paying; no standing price is ranked here while those schedules remain unreconciled.
- Names dispensing pharmacies in its public disclosure
- Marketing describes care, supplies and shipping as included
- Publishes cancellation and refund rules before purchase
- Describes ongoing nursing and portal support
- Headline offers do not reconcile with the legal program price tables
- Cancellation must arrive at least 72 hours before the next billing date
- A multi-month purchase is generally non-refundable for unused time
- Current oral pricing is not established by the older stored figures
Pick it for: Buyers who confirm the exact oral product and program before committing
Not for: Anyone relying on the headline alone or needing a flexible refund policy.
Our verdict
These are compounded oral preparations, not interchangeable versions of an approved semaglutide tablet. Direct Meds identifies sublingual drops and has published a $249 oral figure; confirm the current quote, supply term and renewal before enrolling. Embody's current marketing emphasizes $69/$119 injections, while its legal terms describe gum under separate introductory and flat-price programs. The older $229 oral rate is not reconfirmed, so a claimed $20 saving would be misleading. Ask either provider which formulation and dispensing pharmacy you would receive, what evidence supports that preparation, and what the next charge will be. Embody additionally states a 72-hour cancellation deadline and generally excludes refunds for unused months of a bundle. That matters if you are trying an unfamiliar oral formulation and may want to stop. An injection advertisement cannot answer an oral-price comparison, and neither seller's compounded product inherits the efficacy results of FDA-approved oral semaglutide.
What actually separates them
Direct Meds and Embody differ on published price, names its pharmacy and where you can use it. The table summarizes those terms; confirm any details it does not cover with the provider.
| Direct Meds | Embody | |
|---|---|---|
| Published price | $249/mo | Not published |
| Names its pharmacy | No | Yes |
| Where you can use it | US except MS and LA | US except Louisiana; Nebraska age 19+ |
Before you choose either
Whether these two publish a milligram dose is not settled in our records for both of them, so treat the two prices as not yet comparable and ask each what dose the monthly figure buys. Set the answers against every published price we hold — a lower monthly price at a smaller dose is not the cheaper option.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.